目的利用生物信息学分析iASPP在肝细胞癌(HCC)中的表达及其与HCC患者预后的相关性,并挖掘iASPP对P53靶基因的调控,进而预测iASPP与其他基因共同调控HCC发生发展的关系。筛选影响HCC预后的分子标志物与潜在靶点。方法通过数据库数据分析...目的利用生物信息学分析iASPP在肝细胞癌(HCC)中的表达及其与HCC患者预后的相关性,并挖掘iASPP对P53靶基因的调控,进而预测iASPP与其他基因共同调控HCC发生发展的关系。筛选影响HCC预后的分子标志物与潜在靶点。方法通过数据库数据分析肝癌组织和正常肝组织中iASPP表达差异。选取HCC中iASPP的基因表达谱及相关临床和病理资料,根据iASPP的表达水平将HCC患者分为iASPP高表达组和低表达组,运用SPSS进行生存分析及P53靶基因的表达差异分析,进一步分析P53靶基因表达水平对HCC生存的影响。结果对TCGA数据库、Human Protein Atlas数据库和Oncomine数据库的数据分析,结果显示肝癌组织中iASPP基因表达较正常肝组织明显升高(P=0.001)。肝癌患者中,iASPP高表达患者整体生存较低表达患者更差(P<0.05),无病生存期和无进展生存期有差异但不显著。iASPP高表达患者P53代表性靶基因PMAIP1、RAP2B、BBC3、HES2表达水平较低表达患者显著升高;通过对Human Protein Atlas数据库数据研究PMAIP1、RAP2B、BBC3、HES2表达量与HCC的生存关系,发现PMAIP1(P=0.0020)、RAP2B(P=0.00016)、HES2(P=0.00026)影响HCC患者总体生存。结论iASPP在HCC组织中高表达,并影响HCC患者的预后。iASPP高表达可能通过影响P53靶基因PMAIP1、RAP2B、BBC3、HES2的表达水平,进而发挥促肿瘤细胞增殖的作用。iASPP、PMAIP1、RAP2B、HES2表达量与总体生存有关,有望成为判断HCC预后的分子标志物指标。展开更多
Objective： The aim of this study was to explore the relationship between p53 gene and triple-negative breast cancer （TNBC）, and determine that whether p53 gene could be a new effective therapeutic target. Methods：...Objective： The aim of this study was to explore the relationship between p53 gene and triple-negative breast cancer （TNBC）, and determine that whether p53 gene could be a new effective therapeutic target. Methods： We identified studies with quantitative data on the relation of p53 gene and TNBC through searching 12 databases online （Oct. 1999-Oct. 2012） and reviewing the references, which were written in English or Chinese. Summary estimates of odds ratio （OR） was calculated using the fixed-effects model or the random-effects model as appropriate. Results： We identified 12 eligible stud- ies with 1532 cases of TNBC patients and 6329 controls of non-TNBC patients. The test for homogeneity resulted in X^2 = 200.16 （P 〈 0.05）, it showed significant heterogeneity so that a random effect model was applied. Our results showed that the expression of p53 gene could be much stronger in TNBC group than that in non-TNBC group [OR = 2.10, 95% confidence interval （CI） = 1.21-3.65]. In ethnicity-subgroup analysis, we found that in Caucasian group, the expression of p53 gene were stronger in TNBC group （OR = 2.60, 95% CI = 1.21-5.57）, but there was no statistical significance in Asian group （OR = 1.69, 95% CI = 0.83-3.45）. Conclusion： P53 gene could be an effective predictor and a good therapeutic target for TNBC patients in the future, especially in Caucasian. Further researches focusing on p53 gene would gain a breakthrough in the treatment of TNBC.展开更多
文摘目的利用生物信息学分析iASPP在肝细胞癌(HCC)中的表达及其与HCC患者预后的相关性,并挖掘iASPP对P53靶基因的调控,进而预测iASPP与其他基因共同调控HCC发生发展的关系。筛选影响HCC预后的分子标志物与潜在靶点。方法通过数据库数据分析肝癌组织和正常肝组织中iASPP表达差异。选取HCC中iASPP的基因表达谱及相关临床和病理资料,根据iASPP的表达水平将HCC患者分为iASPP高表达组和低表达组,运用SPSS进行生存分析及P53靶基因的表达差异分析,进一步分析P53靶基因表达水平对HCC生存的影响。结果对TCGA数据库、Human Protein Atlas数据库和Oncomine数据库的数据分析,结果显示肝癌组织中iASPP基因表达较正常肝组织明显升高(P=0.001)。肝癌患者中,iASPP高表达患者整体生存较低表达患者更差(P<0.05),无病生存期和无进展生存期有差异但不显著。iASPP高表达患者P53代表性靶基因PMAIP1、RAP2B、BBC3、HES2表达水平较低表达患者显著升高;通过对Human Protein Atlas数据库数据研究PMAIP1、RAP2B、BBC3、HES2表达量与HCC的生存关系,发现PMAIP1(P=0.0020)、RAP2B(P=0.00016)、HES2(P=0.00026)影响HCC患者总体生存。结论iASPP在HCC组织中高表达,并影响HCC患者的预后。iASPP高表达可能通过影响P53靶基因PMAIP1、RAP2B、BBC3、HES2的表达水平,进而发挥促肿瘤细胞增殖的作用。iASPP、PMAIP1、RAP2B、HES2表达量与总体生存有关,有望成为判断HCC预后的分子标志物指标。
基金supported by a grant from the Key Project of National 12th Five-Years Research Program of China (No. 2012ZX-09303016-002)
文摘Objective： The aim of this study was to explore the relationship between p53 gene and triple-negative breast cancer （TNBC）, and determine that whether p53 gene could be a new effective therapeutic target. Methods： We identified studies with quantitative data on the relation of p53 gene and TNBC through searching 12 databases online （Oct. 1999-Oct. 2012） and reviewing the references, which were written in English or Chinese. Summary estimates of odds ratio （OR） was calculated using the fixed-effects model or the random-effects model as appropriate. Results： We identified 12 eligible stud- ies with 1532 cases of TNBC patients and 6329 controls of non-TNBC patients. The test for homogeneity resulted in X^2 = 200.16 （P 〈 0.05）, it showed significant heterogeneity so that a random effect model was applied. Our results showed that the expression of p53 gene could be much stronger in TNBC group than that in non-TNBC group [OR = 2.10, 95% confidence interval （CI） = 1.21-3.65]. In ethnicity-subgroup analysis, we found that in Caucasian group, the expression of p53 gene were stronger in TNBC group （OR = 2.60, 95% CI = 1.21-5.57）, but there was no statistical significance in Asian group （OR = 1.69, 95% CI = 0.83-3.45）. Conclusion： P53 gene could be an effective predictor and a good therapeutic target for TNBC patients in the future, especially in Caucasian. Further researches focusing on p53 gene would gain a breakthrough in the treatment of TNBC.
